Open an account

Editas Medicine

EDIT · NASDAQ

$2.58+$0.16 (+6.61%)TodayMarket closed ·
Prev close $2.42

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Employees
87
Headquarters
Cambridge, Massachusetts
Listed
Feb 3, 2016
Sector
Health Care
Industry
Biotechnology
Website
editasmedicine.com

EDIT key statistics

Market cap
396.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.60M
Volume
2.27M
Open price
$2.40
High today
$2.67
Low today
$2.35
52 Week high
$4.28
52 Week low
$1.66

Editas Medicine (EDIT) at a glance

As of Oct 20, 2026, Editas Medicine (EDIT) shares are priced at $2.58, giving the company a market cap of 396.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.35 and $2.67. The current price is 9.8% above the day's low and 3.2% below its high.

Volume so far is 2.27M shares, in line with the average of 2.60M shares a day.

Over the past year Editas Medicine has ranged from $1.66 to $4.28, and now sits 35% of the way up that range.

Editas Medicine met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.15 per share against an estimate of -$0.2753.

The average analyst price target is $6.12, 137.2% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $6.12
Low
$1.01
Now
$2.58
High
$15.75

EDIT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 27.0% on average.

  1. Q3 FY24: reported -$0.75 per share against an estimate of -$0.7617
  2. Q4 FY24: reported -$0.55 per share against an estimate of -$0.3638
  3. Q1 FY25: reported -$0.92 per share against an estimate of -$0.6009
  4. Q2 FY25: reported -$0.63 per share against an estimate of -$0.3846
  5. Q3 FY25: reported -$0.28 per share against an estimate of -$0.3022
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.2633
  7. Q1 FY26: reported -$0.26 per share against an estimate of -$0.269
  8. Q2 FY26: reported -$0.15 per share against an estimate of -$0.2753

EDIT news

  • Press releaseGlobe Newswire

    Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine

  • Press releaseACCESS Newswire

    Genflow Biosciences PLC Announces Directorate Change

  • Akanksha Bakshi

    Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

  • Press releasePRNewswire

    Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

  • Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Vandana Singh

    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Editas Medicine

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.